Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Update

Ikena Oncology, Inc. (NASDAQ:IKNAGet Free Report) was the recipient of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 1,380,000 shares, a decrease of 9.2% from the April 30th total of 1,520,000 shares. Based on an average daily volume of 324,400 shares, the short-interest ratio is presently 4.3 days. Currently, 5.9% of the shares of the stock are short sold.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright lowered their target price on shares of Ikena Oncology from $11.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, May 29th. Wedbush downgraded Ikena Oncology from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $8.00 to $2.00 in a research report on Wednesday, May 29th.

Get Our Latest Research Report on Ikena Oncology

Ikena Oncology Stock Performance

IKNA traded up $0.05 during trading on Monday, reaching $1.82. 376,998 shares of the company traded hands, compared to its average volume of 377,057. The company has a market cap of $87.83 million, a P/E ratio of -1.12 and a beta of 0.48. Ikena Oncology has a 12-month low of $1.02 and a 12-month high of $7.38. The firm has a fifty day simple moving average of $1.36 and a 200 day simple moving average of $1.53.

Ikena Oncology (NASDAQ:IKNAGet Free Report) last posted its earnings results on Monday, May 13th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.12. As a group, sell-side analysts expect that Ikena Oncology will post -1.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its position in shares of Ikena Oncology by 88.5% in the fourth quarter. SG Americas Securities LLC now owns 20,222 shares of the company’s stock worth $40,000 after buying an additional 9,495 shares in the last quarter. OUP Management Co. LLC purchased a new position in Ikena Oncology during the 3rd quarter valued at approximately $116,000. Bank of New York Mellon Corp increased its stake in Ikena Oncology by 11.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 69,239 shares of the company’s stock worth $300,000 after acquiring an additional 6,901 shares during the last quarter. Marquette Asset Management LLC purchased a new stake in shares of Ikena Oncology during the 1st quarter worth approximately $104,000. Finally, Barclays PLC boosted its position in shares of Ikena Oncology by 2.1% during the 3rd quarter. Barclays PLC now owns 206,545 shares of the company’s stock valued at $894,000 after acquiring an additional 4,343 shares during the last quarter. Institutional investors own 75.00% of the company’s stock.

About Ikena Oncology

(Get Free Report)

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.

Featured Stories

Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.